利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US4298692A Fermentation process for producing a rifamycin derivative 失效
用于生产利福霉素衍生物的发酵方法

Fermentation process for producing a rifamycin derivative
摘要：
New antibiotically active compounds having the basic structure of rifamycin S, namely 3-hydroxyrifamycin S (formula A: X.dbd.>C.dbd.O; R.sup.1 .dbd.OH; R.sup.2 .dbd.H), 3,31-dihydroxyrifamycin S (formula A: X.dbd.>C.dbd.O; R.sup.1 .dbd.R.sup.2 .dbd.OH) and 1-desoxy-1-oxarifamycin S (formula A: X.dbd.--O--; R.sup.1 .dbd.R.sup.2 .dbd.H) ##STR1## are formed by cultivating, under aerobic conditions, a strain of Nocardia mediterranei which is derived from Streptomyces mediterranei ATCC 13 685 as the parent strain and is characterized by the ability to produce at least one of the mentioned compounds. The recombinant strain Nocardia mediterranei DSM 1415 has proved suitable. The mentioned rifamycin S analogues have analogous antibiotic properties to this but have a wider range of action, especially against gram-negative bacteria.
摘要（中）：

具有利福霉素S的基本结构的新型抗生素活性化合物，即3-羟基喜树碱S（式A：X => C = O; R 1 = OH; R 2 = H），3,31-二羟基化合物S（式A：X = C = O; R1 = R2 = OH）和1-脱氧-1-氧硫霉素S（式A：X = -O-; R1 = R2 = H）通过在需氧条件下培养， 作为亲本菌株来源于地塞米松（Streptomyces mediterranei）ATCC13685的诺卡氏菌（Nocardia mediterranei）菌株，其特征在于产生至少一种所述化合物的能力。 重组菌诺卡氏菌DSM 1415已证明是合适的。 所提到的利福霉素S类似物具有类似的抗生素特性，但具有更广泛的作用范围，特别是针对革兰氏阴性细菌。

信息查询
Global Dossier Espacenet
0/0